Although short-term metformin treatment modestly reduced selected markers of inflammation (TNF-α) and oxidative stress, it did not significantly alleviate the histological or molecular features of kidney injury, suggesting limited therapeutic efficacy under the current experimental conditions and dosing regimen. Here, TNF is linked to kidney injury.